BridgeBio Pharma Inc vs iShares 3 7 Year Treasury Bond ETF — how do they compare? BridgeBio Pharma Inc trades at $83.86 (market cap $16.36B), while iShares 3 7 Year Treasury Bond ETF trades at $116.54. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | IEI | |
|---|---|---|
Market Cap | $16.36B | — |
Sector | Health | Fixed Income |
52-Week High | $90.17 | $120.72 |
52-Week Low | $47.29 | $116.16 |
Enterprise Value | $18.14B | — |
Trailing returns across standard periods
Latest headlines on both assets
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →